Tesamorelin: Clinical Evidence, Visceral Fat & FDA Status

Overview

Tesamorelin is a synthetic analogue of human growth hormone-releasing factor. FDA labeling describes the 44-amino-acid sequence of human GRF and a hexenoyl modification attached at the N-terminal region. The UNII is MQG94M5EEO and the CAS number is 218949-48-5.^1,5

In the United States, tesamorelin is the active ingredient in licensed EGRIFTA drug products. Original U.S. approval was 10 November 2010. Current marketed presentations include EGRIFTA SV and EGRIFTA WR, the latter licensed on 25 March 2025.^3,4,1

The approved indication is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Current labeling states that EGRIFTA is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.^1,2

Peptra sells a research-use-only material labeled Tesamorelin, currently as a 10 mg vial. Peptra documentation does not establish that this vial is tesamorelin acetate, or that it has the same excipients, formulation, bioavailability, or pharmaceutical equivalence as an EGRIFTA product. A COA describes an analytical lot; it does not approve a drug. research-material product page tesamorelin COA archive

What tesamorelin is

As a molecular entity, tesamorelin is a GHRH / GRF analogue. FDA labeling describes it as produced synthetically, based on the 44-amino-acid human GRF sequence, with a hexenoyl moiety — a C6 chain with a double bond at position 3 — attached to the N-terminal tyrosine. The approved drug is prepared as tesamorelin acetate.^1,5

Peptra’s research listing describes the same 44-residue backbone and a trans-3-hexenoyl modification on tyrosine, with C-terminal amidation. That is peptide identity for a laboratory material. It is not a salt claim, an excipient claim, or an equivalence claim versus the licensed product. What Is Tesamorelin? keeps those layers apart.

The published mechanism is that of a GHRH analogue: binding at the GRF receptor, stimulation of pituitary somatotrophs, growth-hormone secretion, and a later rise in IGF-1. A biomarker change does not by itself prove fat loss in every population, muscle gain, an anti-aging effect, or an athletic benefit.¹ Tesamorelin: GHRH, growth hormone & IGF-1

What is actually approved

What FDA has approved is not “tesamorelin in general.” It has licensed specific drug products. Current EGRIFTA WR labeling indicates the product for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.¹

That population is not general obesity, not abdominal fat in people without HIV, and not a cosmetic or bodybuilding use. The pivotal trials measured visceral adipose tissue by imaging in people with HIV and abdominal fat accumulation, not a general-population weight-loss program.^6,7

Current labeling also distinguishes formulations. EGRIFTA WR and EGRIFTA SV are not substitutable: the same active ingredient does not make two presentations interchangeable when formulation and labeled preparation differ.^1,2

What approval does not mean

• It does not mean approval for general weight loss. Labeling states that EGRIFTA is not indicated for weight-loss management.¹
• It does not mean approval for general obesity, abdominal fat without HIV, cosmetic use, bodybuilding, anti-aging, or “metabolic optimization.”
• It does not mean that Peptra research material is FDA-approved, is EGRIFTA, or is interchangeable with EGRIFTA.
• It does not mean that a liver-fat trial created an approved liver indication.^11,12

Evidence map

Visceral fat versus body weight

A common search is “tesamorelin weight loss.” FDA labeling answers that search directly: EGRIFTA is not indicated for weight-loss management.¹

The pivotal trials measured visceral adipose tissue by imaging. A percentage reduction in visceral fat is not the same number as a percentage reduction in scale weight. Subcutaneous fat and total body weight can move differently, or barely move, while the visceral compartment changes.^6,7 Tesamorelin and weight loss: visceral fat is not the same as body weight

Liver research

A 2014 randomized trial in 50 people with HIV and abdominal fat accumulation investigated visceral fat and liver fat. A 2019 Lancet HIV trial enrolled 61 people and used hepatic fat fraction as the primary endpoint. The original title uses NAFLD; MASLD is a later label and does not rewrite that title.^11,12

Those studies are clinical research in people with HIV. They do not authorize generalization to people without HIV and they do not create an approved liver indication. Tesamorelin and liver fat keeps that separation.

EGRIFTA versus RUO material

EGRIFTA is a set of licensed drug products. Peptra’s material is a laboratory research peptide. Sharing an active-moiety name does not establish the same salt, the same excipients, the same formulation, the same stability, the same bioavailability, or the same pharmaceutical equivalence.

Labeling already states that even EGRIFTA WR and EGRIFTA SV are not substitutable. That logic applies more strongly to a research vial that is not a licensed product.¹

This page does not provide use, reconstitution, or storage instructions for the approved product, and it does not provide laboratory instructions for the research vial beyond pointing to the product page and the COA archive.

FDA / WADA

Approval information is U.S. regulatory information. This page does not invent a COFEPRIS status. The WADA 2026 Prohibited List, in force from 1 January 2026, names tesamorelin explicitly under S2.2.4, growth hormone releasing factors / GHRH analogues.^14,15,1

Anti-doping status is not a medical decision and does not turn a research material into an approved drug. This page does not discuss detection windows, washout times, or ways to evade testing. Regulatory detail is in Tesamorelin: EGRIFTA, FDA & WADA status.

What we do not know

• Long-term cardiovascular safety of the approved product has not been established.¹
• The core approval evidence is not a general-obesity program that converts visceral-fat reduction into weight-loss efficacy for every person.
• There is no FDA indication for NAFLD, MASLD, or another liver use.
• Pharmaceutical equivalence between Peptra’s research vial and any EGRIFTA formulation is not documented.
• Peptra documentation does not specify whether the material is presented as free base, acetate, or another salt.

Explore Research

• What Is Tesamorelin? GHRH, EGRIFTA & clinical evidence
• Tesamorelin: GHRH, growth hormone & IGF-1
• Clinical trials of visceral fat in people with HIV
• Weight loss versus visceral fat
• Liver-fat / MASLD evidence
• EGRIFTA, FDA & WADA

Analytical Documentation

The tesamorelin certificate archive publishes the 10 mg lot Peptra currently documents. A COA reports analytical information for a research lot. It does not establish EGRIFTA equivalence, pharmaceutical equivalence, FDA approval, or clinical effectiveness. Open the tesamorelin COA archive

The guides How to read a peptide COA and What a 99% purity claim means explain what a certificate can and cannot show.

References

Sources for this hub are listed at the end of the page. Participant counts, approval dates, and label limitations are cited in the body. The tesamorelin hub does not replace official labeling or the primary papers.